US 11,938,179 B2
Methods and compositions for inducing immune responses against Clostridium difficile
Jing-Hui Tian, Germantown, MD (US); Ye Liu, Clarksville, MD (US); Gale Smith, Germantown, MD (US); Gregory Glenn, Poolesville, MD (US); and David Flyer, Olney, MD (US)
Assigned to Novavax, Inc., Gaithersburg, MD (US)
Filed by Novavax, Inc., Gaithersburg, MD (US)
Filed on Aug. 10, 2021, as Appl. No. 17/398,610.
Application 17/398,610 is a continuation of application No. 16/494,517, granted, now 11,123,419, previously published as PCT/US2018/022597, filed on Mar. 15, 2018.
Claims priority of provisional application 62/474,434, filed on Mar. 21, 2017.
Claims priority of provisional application 62/471,636, filed on Mar. 15, 2017.
Prior Publication US 2022/0211834 A1, Jul. 7, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/116 (2006.01); A61K 39/00 (2006.01); A61K 39/39 (2006.01)
CPC A61K 39/116 (2013.01) [A61K 39/39 (2013.01); A61K 2039/55577 (2013.01); A61K 2039/70 (2013.01)] 20 Claims
 
1. A multivalent immunogenic polypeptide comprising
(i) a binary toxin (CDT) portion having an amino acid sequence that compises SEO ID NO: 22 or an amino acid sequence having at least 90% homology to SEQ ID NO: 22;
(ii) a Toxin A portion having an amino acid sequence that comprises SEQ ID NO:24 or an amino acid sequence having at least 90% homology to SEQ ID NO: 24;
(iii) a first Toxin B portion having an amino acid sequence that comprises SEQ ID NO: 23 or an amino acid sequence having at least 90% homology to SEQ ID NO: 23; and
(iv) a second Toxin B portion having an amino acid sequence that comprises SEO ID NO: 25 or an amino acid sequence having at least 90% homology to SEQ ID NO: 25;
wherein each portion is from a C. difficile toxin protein.